Hepatologists, Oncologists, Pathologists, Pharmaco-Epidemiologists, Pharmacologists, Physicians, Physicians - Medicine, Radiation Oncologists, Researchers, Surgical Oncologists
Primary liver cancer is the 6th most common cancer in the world, and the 3rd most common cause of death from malignant disease. More common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern. Metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40–50% of adult patients with extrahepatic primary tumors.
HO publishes artiles addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal highlights significant advances in basic and translational research, and places them in context for future therapy.
Coverage includes: Studies on all types of primary and secondary hepatic cancers, including hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, fibrolamellar carcinoma and mesenchymal cancers of the liver, Clinical trials in hepatic oncology, Diagnosis and imaging, Epidemiology, Palliative care, Pathogenesis, Pathology, Pediatrics, Pharmacoeconomics, outcomes and comparative effectiveness research, Prognosis, Risk factors, Staging
Surveillance, Therapy, including surgery, chemotherapy, chemoembolization, ablation, radiotherapy, hormonal and biological therapies, Translational research and biomarker studies.